Rocuronium

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Surgical Conditions

Conditions

Surgical Conditions

Trial Timeline

Sep 1, 2015 → Apr 1, 2016

NCT ID

NCT02553629

About Rocuronium

Rocuronium is a approved stage product being developed by Merck for Surgical Conditions. The current trial status is completed. This product is registered under clinical trial identifier NCT02553629. Target conditions include Surgical Conditions.

What happened to similar drugs?

6 of 20 similar drugs in Surgical Conditions were approved

Approved (6) Terminated (5) Active (11)

🔄Nivolumab + EverolimusOno PharmaceuticalPhase 3

✅Epoetin alfa + Standard of CareJohnson & JohnsonApproved

✅ErtapenemMerckApproved

✅Sugammadex + RocuroniumMerckApproved

✅Deep neuromuscular blockMerckApproved

🔄Sugammadex + Neostigmine + GlycopyrrolateMerckPhase 3

🔄Insulin infusion with a goalNovo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02812186	Approved	Completed	Dec 27, 2016	Feb 6, 2019	Cholecystitis
NCT02703909	Approved	Completed	May 1, 2016	Oct 1, 2017	Morbid Obesity
NCT02553629	Approved	Completed	Sep 1, 2015	Apr 1, 2016	Surgical Conditions
NCT02320734	Approved	Completed	Feb 1, 2015	Sep 1, 2016	Neuromuscular Block
NCT02025075	Pre-clinical	Completed	Jan 1, 2014	Oct 1, 2015	Intraoperative Complications
NCT00902070	Pre-clinical	Completed	Nov 1, 2007	Oct 1, 2010	Anesthesia

Competing Products

20 competing products in Surgical Conditions

See all competitors

Product	Company	Stage	Hype Score
DFA-02 Antibiotic Gel + DFA-02 Placebo Gel	Dr. Reddy's Laboratories	Phase 2	32
DFA-02 + Placebo	Dr. Reddy's Laboratories	Phase 1/2	29
Celecoxib	Astellas Pharma	Pre-clinical	26
Nivolumab + Everolimus	Ono Pharmaceutical	Phase 3	40
Epoetin alfa + Standard of Care	Johnson & Johnson	Approved	35
HR021618 + HR021618 + Placebo	Jiangsu Hengrui Medicine	Phase 2	31
SHR0410 Injection + Placebo for SHR0410 Injection	Jiangsu Hengrui Medicine	Phase 2	27
Ertapenem	Merck	Approved	43
Sugammadex + Rocuronium	Merck	Approved	43
Deep neuromuscular block	Merck	Approved	43
Ertapenem	Merck	Phase 2/3	38
Sugammadex + Neostigmine + Glycopyrrolate	Merck	Phase 3	40
Ecallantide + Placebo	Merck	Phase 2	27
Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC)	Novo Nordisk	Phase 1	36
Insulin infusion with a goal	Novo Nordisk	Phase 3	40
parecoxib/valdecoxib	Pfizer	Approved	35
Tranexamic acid + Standard of Care	Pfizer	Approved	43
Ibuprofen 250 mg / Acetaminophen 500 mg + Ibuprofen 250 mg + Acetaminophen 650 mg + Placebo	Pfizer	Phase 3	40
valdecoxib + valdecoxib/placebo + placebo	Pfizer	Phase 3	40
PF-04531083 + PF-04531083 + Ibuprofen	Pfizer	Phase 2	27